Sentences with phrase «nilotinib in»

Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition.

Not exact matches

GUMC says its researchers are now planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin in 2016.

Pagan said that a larger, more comprehensive study must be done before determining the drug's true impact, but if the drug's effectiveness is confirmed in such tests, nilotinib could become the first treatment to impede the killing of brain cells that's consistent with Parkinson's, according to NPR.

One such agent nilotinib (Tasigna ® by Novartis), used to treat leukemia, is being studied in patients with Parkinson's and Alzheimer's diseases.

Also, Georgetown holds an issued US patent on related technology for the use of nilotinib for the treatment of certain neurodegenerative diseases and has other pending patent applications in US and foreign jurisdictions.

The adenosine triphosphate (ATP)-- competitive kinase inhibitors imatinib (STI571; trade name: Gleevec), dasatinib, and nilotinib inhibit multiple tyrosine kinases in addition to ABL1 and ABL2 (5).

«If dasatinib or nilotinib can beat Gleevec in the response they elicit, they will offer patients even greater protection from relapse and possibly even better survival,» he said.

In the proof of concept study, 12 patients received nilotinib, an FDA - approved drug for leukemia.

Also, nilotinib was not compared with a placebo or other medications used to treat Parkinson's in the study.

Researchers say that use of nilotinib, in doses much smaller than those used to treat cancer, was welltolerated with no serious side effects.

In a significant, yet unusual judgment the Court of Justice of the European Union (CJEU) upheld the General Court's decision (T - 140 / 12; Teva Pharma v. EMA) that had affirmed the European Medicines Agency's (EMA) rejection of Teva's generic drug application for Glivec ® (active substance - imatinib), not due to the reference product's own orphan drug exclusivity but in view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinibIn a significant, yet unusual judgment the Court of Justice of the European Union (CJEU) upheld the General Court's decision (T - 140 / 12; Teva Pharma v. EMA) that had affirmed the European Medicines Agency's (EMA) rejection of Teva's generic drug application for Glivec ® (active substance - imatinib), not due to the reference product's own orphan drug exclusivity but in view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinibin view of orphan drug exclusivity of a similar medicinal product — Tasigna ® (active substance - nilotinib).

However, the General Court upheld the EMA's decision refusing Teva's generic application for imatinib in view of nilotinib's orphan drug exclusivity pertaining to CML.

Thus, in view of the similarity of Teva's generic product to that of nilotinib and its orphan exclusivity the General Court validated the EMA's rejection of Teva's generic drug application.